Abstract: TRPV1 is a channel expressed highly in small sensory neurons. TRPV1 is a ligand-gated, cation channel that is activated by heat, acid and capsaicin, a principal ingredient in hot peppers. Because of its possible role as a polymodal molecular detector, TRPV1 is studied most extensively. In mice lacking TRPV1, thermal hyperalgesia induced by inflammation is reduced, suggesting a role for mediating inflammatory pain. Activity of TRPV1 is modulated by actions of various kinases such as protein kinase A and C. Furthermore, phosphorylation by Ca 2+ -calmodulin-dependent kinase II is required for its ligand binding. TRPV1 is activated by various endogenous lipids, such as anandamide, N-arachidonoyldopamine, and various metabolic products of lipoxygenases. 12-hydroperoxyeicosatetraenoic acid, an immediate metabolic product of 12-lipoxygenase, activates TRPV1 and shares 3-dimensional structural similarity with capsaicin. Because lipoxygenase products can activate TRPV1 in sensory neurons, upstream signals to lipoxygenase/TRPV1 pathway have been questioned. Indeed, bradykinin, a potent pain-causing substance, is now known to activate TRPV1 via lipoxygenase pathway. However, we cannot overlook the sensitizing effect of bradykinin via the phospholipase C or protein kinase C pathway. Interestingly, histamine, a pruritogenic substance, also appears to use the lipoxygenase/TRPV1 pathway in order to excite sensory neurons. Because of its role in the mediation of nociception, antagonists of TRPV1 are targeted for development of potential analgesics. In the present review, theoretical background of organic synthesis of SC0030, a potent antagonist of TRPV1 is presented.
INTRODUCTION
Nociceptive (painful) neural signals originate in sensory neurons in peripheral tissues. The neural impulses are transmitted to neurons in the spinal cord, which then convey them to specific nuclei in the brain for perception of pain. Thus, sensory nerves or neurons in the periphery are primary sites where adverse stimuli can be converted to nociceptive neural signals. Among numerous ion channels or receptors that mediate cellular signal transduction, novel ion channels that are present in sensory neurons are identified. These channels are capable of changing the membrane potential in sensory neurons, initiating nociceptive impulses along the pain conduction pathways. Thus, these channels are molecular transducers that detect and convert adverse stimuli to neural signals. Because these channels are implicated in the first lines in generation of nociceptive neural signals, blockers of the channels are considered to be potential analgesics for treating pain. Industrial research attention has been focused on developing blockers of these molecular transducers. Thus, identifying or characterizing these channels becomes a prime target in recent pain research.
In the present review, we focus on the vanilloid receptor 1 (now called TRPV1). TRPV1 is a cation channel that has been implicated in mediation of many types of pain and studied most extensively. Current mechanisms underlying the activation, sensitization and desensitization of TRPV1 *Address correspondence to this author at the Sensory Research Center, CRI, College of Pharmacy, Seoul National University, Kwanak, Shinlim 9-dong, Seoul 151-742, Korea; Tel: 82-2-880-7854; Fax: 82-2-972-0596; E-mail: utoh@plaza.snu.ac.kr are presented. Search for endogenous activators of TRPV1 and their involvement in mediation of inflammatory pain signals will be discussed. Finally, a recent works on the development of TRPV1 antagonists based on structural analysis of capsaicin and the endogenous activator for the treatment of pain is also introduced.
Action of Capsaicin on Sensory Neurons
Hot peppers, a major food additive in the globe, were cultivated in the South America long time ago. Hot chili peppers were then introduced to the Western World about 500 years ago. Chili peppers are hot in taste because they contain a major pungent ingredient, capsaicin. Capsaicin causes severe pain when applied to the skin [1, 2] . The painful sensation is aroused because capsaicin excites a subset of sensory neurons in the periphery [3, 4] . Application of capsaicin excites mainly unmyelinated (C-) or small myelinated (Aδ-) fibers. Thus, the selective excitatory action of capsaicin on a subset of sensory neurons was often used as an experimental tool to dissect out nociceptive fibers from mixed peripheral nerves [5] .
The rapid excitatory effect of capsaicin on sensory nerve fibers or sudden intense pain caused by capsaicin suggests that the excitatory effect would be mediated by opening of ion channels that are present in sensory neurons. Earlier biochemical studies showed that capsaicin causes influx of cations such as Rb + or Ca 2+ in cultured dorsal root ganglion, indicating the presence of ion channel activated by capsaicin in sensory neurons [6] . Electrophysiological studies confirmed the presence of ion channels activated by capsaicin. Application of capsaicin induces inward whole-cell currents in cultured sensory neurons [7, 8] . Subsequently, single channel currents activated by capsaicin were identified using patch-clamp technique [9] . Application of capsaicin activates single-channel currents of ion channels that are permeable to various monovalent cations such as Na + , K + , and Cs + as well as a biologically-important divalent, Ca 2+ . Channel conductance of the capsaicin-activated channel, a relative indication of pore size [10] , is about 45 pS at -60 mV holding potential when Na + is a major charge carrier. The capsaicin-activated channel retains an outwardly-rectifying current-voltage relationship, a common channel property of TRP channels [9] . One of the surprising finding of single-channel current recordings is that the capsaicin-activated channel is a ligandgated channel because the channel is activated directly by capsaicin in isolated membrane patches, where none of intracellular second messengers are available. Thus, capsaicinactivated channel is now classified as a ligand-gated channel, like NMDA receptor, glycine receptor, GABA receptor, or nicotinic acetylcholine receptor [9] .
After identifying single-channel currents activated by capsaicin, Julius and his colleagues cloned a gene encoding for capsaicin-induced channel currents using an excellent cloning technique, the functional expression cloning technique [11] . The cloned gene was named as vanilloid receptor 1 because it is activated by vanilloid analogs. Rat vanilloid receptor 1 has 2, 514 nucleotides and encodes a protein that has 838 amino acids with molecular weight of 95 KDa. Predicted topology of the cloned capsaicin channel indicates that it belongs to TRP channel family, which was initially identified and implicated in visual signal process in the eyes of flies, Drosophila melanogaster. According to new nomenclature of TRP family, vanilloid receptor 1 is now called as TRPV1 [12] [13] [14] . Like many other TRP channels, TRPV1 has six transmembrane domains and two intracellular cytosolic tails in N-and C-termini. The N-terminus in TRPV1 contains three ankyrin repeats (Fig. 1) . The cloned channel, TRPV1, retains most of the channel properties found in native capsaicin-activated channel in sensory neurons, such as channel conductance, ion selectivity or the current-voltage relationship except the pharmacological profile to vanilloids [11, 15] . In addition to capsaicin, noxious heat over 43 o C also activates TRPV1 in a temperature dependent manner [16] , suggesting that TRPV1 is able to detect noxious heat. In addition, TRPV1 is also activated by extracellular acid [16] . Because tissues become acidic during inflammation or ischemia, extracellular acidity in tissues increases. Thus, extracellular acid becomes a relevant stimulus that can activate TRPV1 during inflammation. Identification of TRPV1 makes it possible to determine tissue distribution of TRPV1 in our body. TRPV1 is expressed highly in dorsal-root ganglia and trigeminal ganglia, where sensory neurons cluster. TRPV1 is expressed in unmyelinated or small myelinated fibers that are known to mediate pain [11, 16] . In addition, TRPV1 appears to be expressed in broader areas in the brain, such as cortex, hypothalamus, and cerebellum [17, 18] . Localization of TRPV1 outside the brain is also reported because it is found in the epithelium of urinary bladder, skin, kidney, and even in mast cells [17, [19] [20] [21] [22] . The wide distribution of TRPV1 suggests some unidentified physiological functions other than nociception.
Because expression of TRPV1 alone is functional when expressed heterologously in Xenopus oocytes or mammalian cells, homomeric structure is thought to be a native subunit structure. Indeed, multimeric structures of recombinant TRPV1 or native channels in sensory neurons were resolved in gels. The stoichiometric analysis revealed that TRPV1 appears to form a tetramer containing four-identical subunits like voltage-gated K + channels [23] . However, heteromultimeric structures with TRPV3, a homolog that is activated by heat over 39 0 C but not by capsaicin [24] [25] [26] , have been proposed because TRPV1 is co-expressed in DRG neurons and can associate with TRPV3 [25] .
Physiological Role of TRPV1
In order to assess physiological roles of TRPV1 in vivo , mice deficient of TRPV1 were generated by two groups of scientists [27, 28] . As expected, sensory neurons of the TRPV1-null mice were completely insensitive to capsaicin and acid [27, 28] . TRPV1-null mice impair nociceptive behavioral responses to vanilloid applications to skin. However, phenotypes of the null mice to noxious heat are slightly different between the two groups of knock-out animals. The null mice generated by the Julius group clearly show hypoalgesic responses to noxious heat stimuli [27] . In contrast, the TRPV1-null mice generated by the Davis group do not show analgesic or hypo-algesic thermal behavioral responses to noxious heat when tested by hot plate or tail-flick protocol [28] . However, when tissues are inflamed, both groups observe that withdrawal responses of the null mice to noxious heat are impaired [27, 28] . Thus, it is now generally accepted that TRPV1 is required for mediation of thermal hyperalgesia during a pathological condition such as inflammation.
Sensitization of TRPV1
Like many other channels, TRPV1 contains multiple phosphorylation sites in its amino acid sequence for protein kinase A (PKA), protein kinase C (PKC), and Ca 2+ /calmoduline-dependent protein kinase II (CaMKII). The presence of multiple phosphorylation sites in TRPV1 suggests possible regulatory actions by these kinases. Indeed, sensitization of TRPV1 by these kinases has been proposed. Among them, modulatory action of PKC on TRPV1 has been intensively studied. Initially, it has been known that activation of PKC sensitizes sensory neurons to heat, eliciting a greater response to repeated heat stimuli [29, 30] . Inhibition of PKC activity blocks the augmenting effect of PKC on heat response of sensory neurons [30] . Because TRPV1 is activated by heat, the sensitizing effect of PKC on heat response of sensory neurons leads to an idea of a possible modulation of TRPV1 by PKC. Indeed, stimulation of PKC by a phorbol ester greatly augments TRPV1 responses to capsaicin, anandamide, heat, and acid [31] [32] [33] . Stimulation of PKC by bradykinin (BK) receptor subtype 2 (B2 receptor) or P2Y receptor (ATP receptor) also augments capsaicin response [31, 34] . BK is known to augment current responses of TRPV1 to heat via PKC pathway [35] . Furthermore, mutations on potential phosphorylation sites for PKC such as Ser 502 or Ser 800 significantly reduce the augmenting effect of PKC on TRPV1 [33] . Thus, phosphorylation of TRPV1 augments its activity when PKC is stimulated by extracellular signals such as BK or ATP. But, the action of PKC appears to be limited to sensitization of TRPV1, not to activation of TRPV1 by capsaicin because mutations at the PKC phosphorylation consensus sites do not block activation of TRPV1 by capsaicin [33] .
Phosphorylation by PKA has been implicated in sensitizing TRPV1, too, which is believed to account for the sensitizing effect of sensory neurons by prostaglandin. Prostaglandin, another inflammatory mediator, causes inflammation-induced hyperalgesia [36] and augments or sensitizes sensory neurons to various noxious stimuli [37] . Interestingly, stimulation of PKA by application of forskolin or 8-bromo-cyclic AMP augments TRPV1 responses to heat or capsaicin [38, 39] . In addition, a putative PKA phosphorylation site, Ser 502 residue appears to mediate PKA-induced sensitization to heat because mutation of Ser 502 to alanine greatly reduces the PKA-induced sensitization to heat [38] .
Thus, in addition to PKC, activation of PKA also appears to sensitize TRPV1.
Recently, another model of TRPV1 sensitization has been proposed. Chuang and colleagues reported that phosphatidylinositol-4, 5-biphosphate (PIP 2 ) constitutively inhibited TRPV1 such that sequestering PIP 2 from the plasma membrane by applying monoclonal antibody of PIP 2 or stimulation of phospholipase C (PLC) greatly augmented TRPV1 responses to heat, acid, and capsaicin [40] . The augmenting effect of PLC is thought to result from the hydrolysis of PIP 2 by PLC from the plasma membrane, thus, depleting PIP 2 . Pretreatment of cells expressing TRPV1 with BK or nerve growth factor induces more than 10-fold increase in acid and capsaicin responses [40] . Thus, the augmenting effects of BK or nerve growth factor are suggested to be mediated by the hydrolysis of PIP 2 by PLC [40, 41] .
Activation Mechanism by Phosphorylation by CaMKII
After repeated or prolonged application of capsaicin in high dose, animals become unresponsiveness to various adverse stimuli [42] . In addition, cellular responses of sensory neurons to capsaicin become diminished or reduced after prolonged application of capsaicin [43] [44] [45] [46] [47] [48] [49] [50] . Capsaicininduced desensitization of sensory neurons leads to a strong, naloxone-independent analgesia so that capsaicin and its analogs have been used or developed as potential analgesics [51, 52] . Desensitization of sensory neurons to capsaicin further suggests a possible desensitization occurring at TRPV1. Indeed, capsaicin-induced currents in TRPV1-expressing cells become desensitized during prolonged or repeated applications of capsaicin [11, 39, 53] . Thus, desensitization of TRPV1 in part appears to account for the desensitization of sensory neurons.
Even though desensitization of TRPV1 or sensory neurons induced by repeated or prolonged capsaicin application is well defined, the underlying mechanisms are still elusive. Recently, our group provides compelling evidence for mechanisms underlying the desensitization of TRPV1. Initially, Docherty and colleagues [49] suggested that the desensitization of capsaicin receptor depends on extracellular Ca 2+ and activity of calcineurin, a Ca 2+ -calmodulin dependent phosphatase. They found that calcineurin greatly reduced the capsaicin-induced desensitization of sensory neurons. This report further suggests that dephosphorylation of TRPV1 leads to the desensitization. Likewise, we also could confirm that dephosphorylation by calcineurin reduces desensitization because application of FK-506, a calcineurin inhibitor to sensory neurons blocks the desensitizing effect of capsaicin [53] . Furthermore, we identified a kinase that reversed desensitization of TRPV1 in vivo. For example, when CaMKII was applied to membrane patches, channel activity of TRPV1 was recovered from the desensitized state [53] . Application of PKC, PKA or protein tyrosine kinase failed to recover activity of the desensitized TRPV1. TRPV1 has five phosphorylation consensus sites for CaMKII. Among these consensus sites, Ser 502 and Thr 704 are targeted for phosphorylation by CaMKII because mutation of both amino acids to non-phosphorylatable amino acids leads to a complete loss of activation of TRPV1 by capsaicin [53] . Furthermore, the TRPV1 mutant looses binding ability to a potent agonist of TRPV1, [ 3 H]-resiniferatoxin, which clearly suggests that phosphorylation of these sites possibly by CaMKII is required for ligand binding. When TRPV1 is desensitized after prolonged application of capsaicin, binding ability to [ 3 H]-resiniferatoxin is markedly reduced. In vivo phosphorylation study shows that TRPV1 is fully phosphorylated in the resting state. When human embryonic kidney cells transfected with TRPV1 are treated with capsaicin for inducing the desensitization, phosphorylation of TRPV1 is markedly reduced, confirming the hypothesis that TRPV1 becomes dephosphorylated when desensitized by the capsaicin treatment. In addition, in vivo phosphorylation is also depressed in the TRPV1 mutant that disables the CaMKII phosphorylation sites [53] . These results clearly suggest that phosphorylation of TRPV1 at either Ser 502 or Thr 704 is sufficient and necessary for its binding to vanilloids. Once the amino acid residues are dephosphorylated by calcineurin, ligand cannot bind TRPV1, leading to desensitization, a condition that receptors cannot operate even in the continued presence of their ligands. This is a unique control mechanism for activation by ligand because no other ligandgated channels require phosphorylation for their ligand binding. Thus, based on these results, one can imagine a state diagram for the activation or desensitization state of TRPV1 (Fig. 2) . Thus, it appears that the dynamic balance between phosphorylation and dephosphorylation of TRPV1 by CaMKII and calcineurin controls the activation/desensitization states by regulating ligand binding.
Apart from the activation mechanism of TRPV1 by CaMKII, desensitization of TRPV1 by other mechanisms was also proposed. Bhave and colleagues found that stimulation of PKA eliminates the desensitization of TRPV1 to repeated application of capsaicin [39] . With mutagenesis and in vitro phosphorylation, Bhave and colleagues identified a phosphorylation site, Ser 116 that controlled desensitization of TRPV1. When Ser 116 is replaced with aspartate, mimicking constitutive phosphorylation, desensitizing currents to repeated application of capsaicin are blocked [39] . Numazaki and her colleagues also found that physical association of calmodulin to TRPV1 might control some form of TRPV1 desensitization [54] . Calmodulin binds TRPV1, especially a small segment in the C-terminus. Furthermore, a mutant of TRPV1 lacking the calmodulin binding site blocks tachyphylactic current response to a brief challenge of capsaicin. However, the mutant fails to block desensitization of current response to prolonged application of capsaicin [54] . Thus, desensitization of TRPV1 appears to be complex requiring multiple control mechanisms. It would be conceivable that either attenuation of activation or inhibition of sensitization would lead to desensitization of the channel. Whatever the desensitization/sensitization mechanisms are, phosphorylation/dephosphorylation stress impinging on TRPV1 appears to control a wide range of excitabilities in response to various noxious stimuli.
Vanilloid-Binding Sites of TRPV1
Ligands of TRPV1 seem to act on TRPV1 from the intracellular side [55] . This is another unique property pertaining to TRPV1, different from other ligand-gated channels, such as NMDA receptor or nicotinic receptor because ligands of these channels bind from the extracellular space. Capsaicin is capable of activating TRPV1 either when it is applied to the intracellular side of a membrane patch or when applied to the extracellular side of a membrane patch containing TRPV1. This is possible because capsaicin is highly lipophilic so that it can pass the plasma membrane easily. Thus, it seems difficult to determine whether capsaicin acts on TRPV1 from the intracellular side or not. In order to solve this problem, Jung and colleagues [55] used a membrane impermeable analog of capsaicin, DA-5018•HCl. DA-5018•HCl is hydrophilic and cannot cross the plasma membrane easily. Thus, Jung and her colleagues were able to determine that DA-5018•HCl activated TRPV1 when it was applied only to the intracellular side of patch membrane, not to the extracellular side [55] . It is now generally accepted that capsaicin acts on and binds TRPV1 from the intracellular side. More direct evidence for the presence of binding site at the intracellular domain came from mutational study [56] . After constructing a series of deletion mutants of TRPV1, Jung and her colleagues were able to locate specific sites in TRPV1 that were required for binding to ligand [56] . The two critical sites for capsaicin binding are Arg 114 and Glu 761 at the Nand C-termini of TRPV1, respectively. When these two sites were mutated or deleted, these TRPV1 mutants fail to respond to capsaicin with concomitant loss of their ability to bind a vanilloid, [ 3 H]-resiniferatoxin [56] . Because these amino acids are charged and located in the cytosolic part of TRPV1, the two regions would be implicated in hydrophilic interaction of TRPV1 with vanilloids [56] . In addition to these sites in N-and C-termini of TRPV1, a region in the intracellular linker located between the second and third transmembrane domain, thus called 'the TM3 region', is proven to be critical for hydrophobic interaction with vanilloids [57] . Interestingly, birds have a TRPV1 ortholog even though they do not seem to taste 'hot' sensation when they eat hot peppers. The impairment of hot taste of peppers in the bird is thought to result from the fact that avian TRPV1 does not respond to vanilloid. Avian TRPV1 has a different sequence in the TM3 region compared to that of mammalian TRPV1s [57] . When the TM3 region of avian TRPV1 is replaced with the corresponding segment of rat TRPV1, the TRPV1 chimera responds to capsaicin [57] . With additional experiments, Jordt and Julius (2002) conclude that the TM3 region is necessary for binding to vanilloids. Because this region is close to or embedded in the plasma membrane, TM3 is surrounded by the hydrophobic environment. Thus, the TM3 region is now considered to be important for hydrophobic interaction with capsaicin. The TM3 region and Arg 114 and Glu 761 in TRPV1 consist of a long known biding pocket to vanilloids [58] .
Endogenous Activators of TRPV1
Vigorous studies on searching for endogenous ligands to TRPV1 were begun following molecular identification of TRPV1. It is analogous to morphine receptors whose endogenous ligands, endorphin, dynorphin or enkephalin were discovered after identification of morphine receptors. The presence of endogenous activators of TRPV1 was determined in part in an in vivo experiment because c-fos expression in the dorsal horn of the spinal cord induced by inflammation is reduced by capsazepine [59] , a capsaicin receptor blocker [60] . This result suggests that during inflammation, endogenous activator of TRPV1 is released and causes hyperalgesia by opening TRPV1. Indeed, two types of lipids, endocannabinoids and eicosanoids of lipoxygenase (LO) products, are found to activate TRPV1 [61, 62] .
Because ligand-binding sites are known to be located in the intracellular side of TRPV1, we initially tested intracellular second messengers for TRPV1 activation in order to find the possible endogenous activators. None of intracellular second messengers, such as Ca 2+ , ATP, ADP, cyclic AMP, and NADPH, etc, activate TRPV1. However, we found that metabolic products of LOs, such as 12-hydroperoxyeicosatetraenoic acid (12-HPETE), were capable of activating TRPV1 [62] . Consistent with this idea, activation of TRPV1 by products of LOs mediates inflammatory pain. When applied to skin, various LO products induce painrelated behavior [63] . LO products are produced during inflammation [64] . Furthermore, products of LOs act directly on K + channels in Aplysia sensory neurons [65] and mammalian cardiac muscle cells [66] , suggesting a role of LO products as second messengers.
When applied to the bath of inside-out patches of sensory neurons or human embryonic cells transfected with TRPV1, 12-HPETE activates single-channel currents that are blocked by capsazepine. Furthermore, channel property of singlechannel currents activated by 12-HPETE, such as conductance or the outwardly-rectifying current-voltage relationship, is identical to that obtained by capsaicin, indicating that the channel activated by 12-HPETE are nonetheless TRPV1.
Various other metabolic products of LOs are also capable of activating TRPV1 [62] . The dose-response relationships reveal that 12-and 15-HPETE, 5-and 15-hydroxyeicosatetraenoic acids (5-and 15-HETEs), or leukotriene B 4 are most efficacious or potent in activating TRPV1. Anandamide, an endocannabinoid that is thought to be an agonist for cannabinoid receptor subtype 1, also activates the channel but with much lower efficacy than 12-HPETE [61, 62] . Other eicosanoids such as prostaglandins are also tested for activation of TRPV1 because prostaglandins sensitize nociceptive fibers. But, prostaglandins do not activate TRPV1. In addition, other saturated or unsaturated fatty acids, such as arachidic, linoleic, linolenic, and arachidonic acids are also tested for their activation of TRPV1. They do not activate TRPV1 or are weak in activating TRPV1, if any [62] . Recently, another type of arachidonic-acid metabolite, Narachidonoyl-dopamine (NADA) is also suggested to be a candidate for endovanilloids because it binds and activates TRPV1 [67] .
Binding Capacity of 12-HPETE to TRPV1
Because 12-HPETE activates TRPV1, it is likely that 12-HPETE can act on TRPV1 directly. But, the actual binding to TRPV1 is not known. Shin and colleagues now determined the actual binding of 12-HPETE to TRPV1 using competition assay technique [68] . The competition assay is a test of binding affinity of 12-HPETE to TRPV1 using a radio-labeled high-affinity agonist of TRPV1, 3 H-resiniferatoxin ( 3 H-RTX) [69, 70] . Human embryonic kidney (HEK) cells expressing TRPV1 show specific binding of 3 H-RTX. When added with various concentrations of 12-HPETE, the specific binding of 3 H-RTX to TRPV1 is inhibited in a dose-dependent manner. Interestingly, the inhibition constant (K i ) of 12-HPETE in inhibiting 3 H-RTX binding to TRPV1 is 0.35 µM, which is lower than K i of capsaicin.. These results suggest that 12-HPETE actually binds TRPV1 with a higher affinity to TRPV1 than capsaicin [68] .
Structural Comparison of Capsaicin with 12-HPETE and Anandamide
Because both of 12-HPETE and capsaicin bind and activate TRPV1, one can easily imagine a structural similarity between capsaicin and 12-HPETE. But as shown in Fig. (3) , the chemical structures of capsaicin and 12-HPETE look different. Thus, a question about the possible Fig. (3) . Chemical structures of 12-HPETE and capsaicin. 
12-HPETE
Capsaicin similarity in three-dimensional structures is raised [62] . To answer this question, 3-D structures of capsaicin and 12-HPETE, 15-HPETE, 5-HETE, and leukotriene B 4 in the lowest energy state are extracted and superimposed with each other by a computer modeling. As expected, the 3-D structure of capsaicin fits well to that of the S-shaped 12-HPETE [62] . Especially, the functional moieties in capsaicin such as phenolic hydroxide or amide moieties overlap well with the carboxylic acid and hydroperoxide moieties in 12-HPETE, respectively. These two regions in capsaicin are thought to be key functional moieties for hydrogen bond interactions with capsaicin receptor [58] . The aliphatic chain of 12-HPETE fits well with the 'C-region' of alkyl chain of capsaicin [58] . The structural similarity between capsaicin and 12-HPETE now explains why the two chemicals act on the same receptor, TRPV1. Other eicosanoids, such as 15-HPETE, 5-HETE and leukotriene B 4 , or anandamide show less structural similarity with capsaicin [62, 71] .
Bradykinin Signaling Pathway to TRPV1
Since it is now known that 12-HPETE and other 12-LO products are potential candidates for endogenous activators of TRPV1, the next question is what stimulates 12-LO in sensory neurons. We came to an idea that BK would be a candidate. BK is an inflammatory mediator and potent pain causing substance that is released when tissues are damaged. Being a pain-causing substance, BK excites or sensitizes sensory neurons [72, 73] . Although excitatory effect of BK is well-understood, precise molecular mechanisms underlying its excitatory effect is not known. BK stimulates phospholipase C (PLC) that in turn results in the release of inositol(1, 4, 5)-triphosphate and 1, 2-diacylglycerol in sensory neurons [74, 75] . Furthermore, BK also produces arachidonic acid (AA) in sensory neurons [75, 76] . Because BK releases AA, a key substrate for LO in sensory neurons, we thus hypothesized that BK would activate TRPV1 via stimulating the PLA 2 /LO pathway. In order to prove this, we attempted to determine whether BK evoked inward currents would be reduced or blocked by capsazepine, a TRPV1 antagonist. As expected, application of BK to sensory neurons evokes slow, small inward currents [68] . Whole-cell currents evoked by BK are reduced by co-application with capsazepine [68] . Similarly, application of BK evokes single-channel currents that also are reduced by co-application of capsazepine. These results from electrophysiological recordings clearly suggest that BK indeed activates TRPV1. When BK is applied to sensory neurons, BK excites sensory neurons, evoking a volley of action potentials. The action potential volleys are also inhibited by co-application of BK with capsazepine, nordihydorguaiaretic acid (NDGA, a nonselective LO inhibitor), and quinacrine (an inhibitor of PLA 2 ). Thus, these results clearly suggest that BK excites sensory neurons via the PLA 2 /LO/TRPV1 pathway. Similar experiments are also confirmed by recordings of action potentials from cutaneous sensory nerve fibers using the in vitro skin-nerve preparation [1, 77, 78] . When BK is applied to cutaneous unmyelinated nerve fibers, BK produces volleys of action potentials, an indication of excitation. The BK-induced excitation of sensory nerve fibers is greatly depressed after co-treatment of capsazepine, quinacrine, or NDGA. These results also confirm that BK excites sensory neurons via the PLA 2 /LO/TRPV1 pathway [68] . In contrast, the BK-evoked excitation of sensory nerve fibers is not reduced by co-application of indomethacin, a cyclooxygenase inhibitor, indicating that BK excites sensory neurons via LO/TRPV1 pathway, not via the cyclooxygenase/TRPV1 pathway. In Ca 2+ imaging study where cultured sensory neurons are incubated with a fluorescent Ca 2+ sensitive dye, Fluoro-3 AM, sensory neurons become bright in fluorescence after application of BK, indicating Ca 2+ influx into the cells. The Ca 2+ influx induced by BK treatment is markedly reduced by co-application of capsazepine, quinacrine, NDGA, or baicalein (a 12-LO specific inhibitor). In this experiment, too, indomethacin fails to reduce the BKinduced Ca 2+ influx, which confirms that cyclooxygenase does not mediate the BK signaling [68] .
BK application causes the actual release of LO products [68] . In order to determine whether sensory neurons actually synthesize the LO products upon stimulation by BK, sensory neurons are incubated with 14 C-arachidonic acid, which labels LO products with 14 C isotopes. As a result, a radiolabeled peak in a HPLC trace is observed. The peak exhibits an identical retention time to that of 12-HETE, an immediate downstream metabolite of 12-HPETE. To further confirm that the chemical constituent of the radio-labeled peak, the fraction of the isotope-labeled peak is collected. The chemical in the fraction analyzed with an LC/Mass spectrometer confirms a molecular peak of 12-HETE. Furthermore, using an enzyme immunoassay method that utilizes 12-HETE-specific polyclonal antibody, a more than 10-fold increase in the level of 12-HETE by BK in sensory neurons is observed [68] . These results now indicate that BK indeed releases 12-HETE, a metabolic product of 12-LO in sensory neurons [68] .
Recently, contribution of the PLA2/LO/TRPV1 pathway to the BK-induced nociception has been tested in vivo [79] . BK-induced pain-related behaviors are reduced by inhibition of PLA 2 or LO. Furthermore, injection of BK into the hindpaw increases the level of leukotriene B4, a downstream metabolite of 5-LO [79] . These results clearly suggest that BK indeed excites nociceptive sensory neurons by the PLA2/LO/TRPV1 pathway in vivo. However, one should not forget ability of BK in sensitizing TRPV1 via PLC or PKC pathway as discussed above. Indeed, Ferreira and his colleagues also found that BK-induced nociception is also decreased by application of inhibitors of PLC and PKC [79] . Thus, sensory neurons appear to use multiple pathways for their activation or sensitization by BK.
Histamine Signals to TRPV1
We further hypothesized that the PLA2/LO/TRPV1 pathway would mediate other nociceptive signals to sensory neurons, too. Histamine is considered to be a possible candidate. Histamine released from mast cells after tissue injury is known to cause itch and excite polymodal nociceptors, sensory nerve fibers that are specialized for pain sensation [80] [81] [82] [83] . Even though excitatory action of histamine on sensory neurons is well defined, its action mechanism on sensory neurons is not clearly understood. Histamine is known to produce arachidonic acid via activation of PLA 2 in Chinese hamster ovary cells [84] . Furthermore, sensory neurons that are excited by histamine respond mostly to capsaicin. Therefore, it seems likely that histamine excites sensory neurons via stimulating the PLA 2 /LO/TRPV1 pathway. To test for the excitation of sensory neurons by histamine, we measured Ca 2+ influx induced by histamine application in cultured sensory neurons using a Ca 2+ sensitive fluorescent dye [85] [85] . Thus, it seems likely that histamine increases Ca 2+ influx by activating TRPV1 via the PLA 2 /LO pathway in sensory neurons. Because BK and histamine use the PLA 2 /LO/TRPV1 pathway, we propose that the signaling pathway would serve as a common pathway for mediating inflammatory signals to the excitation of sensory neurons (Fig. 4) . However, this proposition remains to be studied further for its physiological relevance.
Development of SC0030, a Novel Non-Vanilloid TRPV1 Antagonist
Over the past few years, considerable efforts toward the development of a novel analgesic have been continued since capsaicin was found as an excellent TRPV1 agonist. Because TRPV1 functions as an integral molecule detecting multiple modes of noxious stimuli, one can easily imagine that TRPV1 antagonists would have antinociceptive effects, especially in inflammatory pain [11, 16, 27, 28] . Thus, many research groups are engaged in developing novel TRPV1 antagonists, although the therapeutically useful antagonists are not currently available [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] .
We have looked for non-vanilloid TRPV1 antagonists that might provide the potent analgesic effects but with weaker side effects. This approach is on the basis of the previous studies on TRPV1 agonists and antagonists, as well as our recent findings on endogenous activator, 12-HPETE [62] . The structural similarity of these two molecules was key background for the development. Our molecular modeling studies envisioned three crucial pharmacophoric parts of each molecule, which are characterized as multiple hydrogen bonding part, dipolar interaction part, and hydrophobic part (Fig. 5) . Moreover, the distances between three pharmaco- Fig. (4) . Proposed signaling pathways for bradykinin (BK) or histamine-induced excitation of sensory neurons. phoric parts of 12-HPETE were quite close to the corresponding distances of capsaicin as shown in Fig. (6) .
Thus, our initial work on the development of novel TRPV1 antagonists was focused on the synthesis of a number of carboxylic acids possessing pharmacophoric parts B and C because carboxyl group, which functions as both hydrogen bonding donors and/or acceptors, was anticipated as a novel vanilloid equivalent. In order to determine whether the synthesized analogs activate or antagonize TRPV1, we recorded the single-channel currents of TRPV1 from inside-out patches isolated from cultured sensory neurons. Fig. (7) shows two examples of the novel TRPV1 antagonists, which were developed on the structural basis of 12-HPETE.
We have extended our investigation for the development of TRPV1 antagonists to other type of vanilloid equivalents because the weak antagonistic effects of carboxylic acids were not much improved by structural variation of the pharmacophoric parts B and C. Subsequently, our intensive work Fig. (6) . Comparison of the distances of three pharmacophoric parts. on design, syntheses and in vitro evaluation of numerous synthesized analogs employing single channel assay and 45 
Ca
2+ uptake experiments on cultured sensory neurons led to the optimized structures for the novel TRPV1 antagonists as shown in Fig. (8) .
Initially, thiourea and t-butylbenzyl moiety were fixed as dipolar interaction part and lipophilic part, respectively, because they are known to provide high binding affinity for TRPV1. m-Methoxy group of vanilloid moiety was displaced by the H-bonding acceptors while p-hydroxy group was displaced by H-bonding donors. With this synthesis schemes, we could develop a large number of potent TRPV1 antagonists. Among them, SC0030 deserves a great attention as a potent TRPV1 antagonist with an IC 50 of 0.037 µM [97, 98] and thus becomes one of the most potent non-vanilloid TRPV1 antagonistic ligands. SC0030 was also 16-fold more potent than capsazepine as a known TRPV1 antagonist. Elimination of fluoro group for R 1 decreases the antagonistic effects. However, the higher potency than capsazepine is still exhibited. The analog, which possesses only fluoro substituent for R 2 retains weak antagonistic effects. The analog, which possesses neither fluoro substituent (R 1 ) nor methansulfonamido substituents (R 2 ), completely loses the antagonistic effects.
The optimized synthetic procedure for SC0030 is outlined in Scheme 1. This four-step sequence is relatively practical and efficient. Most importantly, SC0030 can be conveniently synthesized on more than a hundred-gram scale to ensure a substantial quantity for further therapeutic evaluation.
The analgesic effect of SC0030 was evaluated by PBQinduced writhing antinociceptive assay. As shown in Fig. (9) , SC0030 inhibits the writhing in a dose-dependent manner and was almost equipotent or slightly more potent than indomethacin, a nonselective COX inhibitor.
To confirm further the antagonistic effect on TRPV1 in vivo, we performed a capsaicin-induced licking test [99] . In this pain model, SC0030 dose-dependently inhibited the capsaicin-induced pain response. However, SC0030 did not cause any irritant effect such as eye-wiping action when it was instilled to the eye of the rat. One of adverse effects of capsaicin is its hypothermic effect. Systemic injection of resiniferatoxin, a potent agonist of TRPV1, produces hypothermia [100] . Thus, the hypothermic effect would be expected for the newly synthesized TRPV1 antagonist. However, body temperature was not changed significantly after SC0030 administration in the rat. Thus, this novel TRPV1 antagonist would be useful in clinic as a new candidate for non-vanilloid analgesics. 
